These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6871360)

  • 21. Design of multi-centre trials with binary response.
    Dragalin V; Fedorov V
    Stat Med; 2006 Aug; 25(16):2701-19. PubMed ID: 16252268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methodology standards associated with quality reporting in clinical studies in pediatric surgery journals.
    Thakur A; Wang EC; Chiu TT; Chen W; Ko CY; Chang JT; Atkinson JB; Fonkalsrud EW; Grosfeld JL
    J Pediatr Surg; 2001 Aug; 36(8):1160-4. PubMed ID: 11479847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing clinical trials and experiments efficiently with the program package CADEMO.
    Rasch D; Kubinger KD
    Contemp Clin Trials; 2009 Jul; 30(4):354-65. PubMed ID: 19341821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating treatment effects in clinical trials subject to regression to the mean.
    Senn SJ; Brown RA
    Biometrics; 1985 Jun; 41(2):555-60. PubMed ID: 4027329
    [No Abstract]   [Full Text] [Related]  

  • 25. [Multiple testing].
    Bender R; Lange S; Ziegler A
    Dtsch Med Wochenschr; 2007; 132 Suppl 1():e26-9. PubMed ID: 17530590
    [No Abstract]   [Full Text] [Related]  

  • 26. CT2--the clinical trials control tower: overcoming barriers to opening oncology clinical trials.
    Hammond AL; Waller EK; Finkelstein LB
    J Clin Oncol; 2007 Apr; 25(10):1288; author reply 1288. PubMed ID: 17401022
    [No Abstract]   [Full Text] [Related]  

  • 27. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
    Emerson SS
    Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical considerations in the design of clinical trials.
    Carter SK
    Cancer Treat Rep; 1980; 64(2-3):367-71. PubMed ID: 7407773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and conduct issues in surgical clinical trials.
    Neumayer L
    Am J Surg; 2004 Dec; 188(6A Suppl):17S-21S. PubMed ID: 15610888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian design and analysis of two x two factorial clinical trials.
    Simon R; Freedman LS
    Biometrics; 1997 Jun; 53(2):456-64. PubMed ID: 9192445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research methodology: A guarantee for progress in knowledge about infections].
    Carballo Alvarez F
    Rev Esp Quimioter; 2001 Jun; 14(2):126-37. PubMed ID: 11704767
    [No Abstract]   [Full Text] [Related]  

  • 34. [How to prevent hazards and to reduce risk in clinical trials?].
    Czarkowski M
    Pol Merkur Lekarski; 2008 Dec; 25(150):534-8. PubMed ID: 19205390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Data management for clinical trials at the data center].
    Niimi M; Fukuda H; Yamamoto S; Okuyama S; Yamaguchi N
    Gan To Kagaku Ryoho; 1998 Jan; 25(2):253-9. PubMed ID: 9474934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 38. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comment on interim analyses in crossover trials.
    Grieve AP; Senn S
    Biometrics; 1996 Dec; 52(4):1515-20. PubMed ID: 9019232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aspects of biostatistics in adjuvant chemotherapy studies].
    Platz H; Hudec M
    Dtsch Z Mund Kiefer Gesichtschir; 1985; 9(4):292-7. PubMed ID: 3913550
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.